Zealand reports Lyxumia® royalty revenue for the first 9

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand reports Lyxumia® royalty revenue for the first 9 months of 2014

Copenhagen, 2014-10-28 08:03 CET (GLOBE NEWSWIRE) --

  • Lyxumia® royalty revenue to Zealand was DKK 14.1 (EUR 1.9) million for the first 9 months of 2014
  • Continuously high growth quarter-on-quarter with Q3 2014 royalty revenue up 38% from Q2 2014 to DKK 6.0 (EUR 0.8) million

Copenhagen, 28 October 2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) today reports Lyxumia® royalty revenues of DKK 14.1 (EUR 1.9) million for the first 9 months of 2014, based on Sanofi’s global ex-US sales of the product for the period. Lyxumia® was launched in the first markets by end March 2013.

In Q3 2014, royalty revenue was DKK 6.0 (EUR 0.8) million with 50% generated from sales in Western Europe, 25% from sales in Emerging Markets and 25% from sales in the Rest of the World, including Japan. The main contributing countries were the UK, Spain, Japan and Brazil. Royalty revenue generated in Q3 2014 was up 38% compared to Q2 2014.

Sanofi has launched Lyxumia® in over 20 countries and received approval for the product in over 50 countries with several launches planned in Q4 and 2015.

Sanofi plans to resubmit a regulatory filing for Lyxumia® in the US in Summer 2015 following the completion of the ELIXA cardio-vascular safety study, from which Sanofi expects to present top-line results in Q2 2015.

In a comment to this royalty revenue report and the status of Lyxumia®, David Solomon, President and CEO of Zealand, said:

“We are very pleased to witness the increasing market uptake of Lyxumia®, a once-daily prandial GLP-1 agonist with a beneficial effect on weight. Lyxumia® is the first peptide therapeutic from Zealand’s pipeline to be launched, and we believe that the product has great potential to become an important diabetes medicine as marketed by Sanofi. We look forward to following Sanofi’s continued roll-out and to the highly important clinical results of ELIXA, leading to the planned refiling of the product in the US in the Summer of 2015.”

Financial outlook for 2014 and terms of the license collaboration with Sanofi

Zealand’s financial outlook for 2014 remains unchanged, including revenue from milestone payments of DKK 133 (EUR 18) million.

In addition to the DKK 14.1 (EUR 1.9) million for the first 9 months of the year, Zealand will receive further Lyxumia® royalty revenue in Q4. However, no guidance is given on full year royalty revenue, since Sanofi gives no guidance on Lyxumia® sales.

Zealand’s net operating expenses in 2014 are expected at a range of DKK 195-205 (EUR 25-28) million.

Under the license agreement with Sanofi, covering lixisenatide (Lyxumia®) and any combination products which include lixisenatide, Zealand is eligible to receive remaining milestone payments of up to USD 160 million. Further, Zealand is entitled to tiered low double-digit percentage royalties on Sanofi's global sales of Lyxumia® and to fixed low double-digit percentage royalties on global full net sales of LixiLan, the single once-daily injection combination of Lyxumia® with Lantus®, currently in Phase III clinical development and with regulatory filing expected as early as end 2015.

 ***

For further information, please contact:

David H. Solomon, President and Chief Executive Officer
Tel: +45 2220 6300

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: hlh@zealandpharma.com

 

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines, in-house competences in clinical trial design and management and a therapeutic focus on cardio-metabolic diseases. The company has a broad portfolio of therapeutic products – proprietary and partnered.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed world-wide ex-US as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for both products is planned for 2015 ─ summer for Lyxumia® and as early as end 2015 for LixiLan.

Zealand is advancing a pipeline of proprietary, next-generation therapies, including danegaptide (prevention of Ischemic Reperfusion Injury) in addition to several preclinical programs. Partnering represents an important component of strategy to share development risk in large clinical trials, to provide funding and to commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Boehringer Ingelheim, Helsinn Healthcare and Lilly.

For further information: www.zealandpharma.com      Follow us on Twitter @ZealandPharma

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 192

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 87

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 16

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 253

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 264

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 249

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 0

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading

Top 5 Most Recently Viewed Articles

IASO Bio Achieves Major Milestone with Orphan Drug Status

Updated Category News Views 270

IASO Bio Earns Orphan Drug Designation for Breakthrough Therapy IASO Biotherapeutics, a key player in the biopharmaceutical sector, announced an exciting achievement as its groundbreaking treatment, Equecabtagene Autoleucel (Fucaso), received Orphan Drug Designation from the Ministry of Food and Drug Safety. This recognition is particularly significant for adults fighting...

Continue Reading
Transforming Experience: Honda Center's $1 Billion Revamp

Updated Category News Views 387

Transforming Experience: Honda Center's $1 Billion Revamp Honda Center Encore Is A Multi-Year Investment Led by the Samueli Family That Will Redefine the Arena Experience OC Sports & Entertainment (OCSE), connected with the operator of Honda Center, has announced a groundbreaking project known as Honda Center Encore. This ambitious venture involves a significant...

Continue Reading
PIMCO Municipal Income Fund Faces Market Pressures at New Lows

Updated Category News Views 192

PIMCO Municipal Income Fund's Recent Market Performance PIMCO Municipal Income Fund (PMF) has recently faced significant market challenges, as evidenced by its stock hitting a notable 52-week low at a price of $8.82. This decline isn't merely an isolated incident; it reflects ongoing pressures impacting the broader fixed-income sector. Investors are currently navigating...

Continue Reading
Exploring Non-Surgical Solutions for Prostate Health Issues

Updated Category News Views 174

Prostate health became a hot topic for many men over 50, especially with the rise of benign prostatic hyperplasia (BPH)—that uncomfortable enlargement that turns bathroom trips into sprints. Back then, treatment options were shaking up, and PAE was coming onto the scene like it owned the place. PAE vs. Traditional Surgery: The Fight for Relief In an era where...

Continue Reading
Applied Digital Appoints Laura Laltrello as COO for AI Growth

Updated Category News Views 245

Applied Digital Names Laura Laltrello as New COO Applied Digital Corporation (NASDAQ: APLD) is excited to announce the appointment of Laura Laltrello as its new Chief Operating Officer (COO). With an aim to strengthen the Company’s leadership in next-generation data centers and digital cloud solutions, Ms. Laltrello's role signifies a pivotal moment in the Company’s...

Continue Reading